Literature DB >> 20687835

Recurrence after treatment for pulmonary multidrug-resistant tuberculosis.

Mercedes C Becerra1, Sasha C Appleton, Molly F Franke, Katiuska Chalco, Jaime Bayona, Megan B Murray, Carole D Mitnick.   

Abstract

We estimated the proportion of recurrence within 2 years among adults cured by individualized multidrug-resistant tuberculosis regimens in Peru. Among 310 individuals with at least 24 months of follow-up, 16 experienced an episode of recurrent tuberculosis. If we assume the worst for treatment effectiveness-that all 16 episodes were caused by the original tuberculosis strain-then 5.2% (95% confidence interval, 3.0%-8.2%) experienced true relapse. This is an upper-bound estimate of relapse on which new regimens must improve.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20687835     DOI： 10.1086/655892

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  12 in total

1.  Counting pyrazinamide in regimens for multidrug-resistant tuberculosis.

Authors:  Molly F Franke; Mercedes C Becerra; Dylan B Tierney; Michael L Rich; Cesar Bonilla; Jaime Bayona; Megan M McLaughlin; Carole D Mitnick
Journal:  Ann Am Thorac Soc       Date:  2015-05

2.  Rapid detection of rpoB gene mutations conferring rifampin resistance in Mycobacterium tuberculosis.

Authors:  Wanyuan Ao; Stephen Aldous; Evelyn Woodruff; Brian Hicke; Larry Rea; Barry Kreiswirth; Robert Jenison
Journal:  J Clin Microbiol       Date:  2012-04-18       Impact factor: 5.948

3.  Improving outcomes for multi-drug-resistant tuberculosis in the Peruvian Amazon - a qualitative study exploring the experiences and perceptions of patients and healthcare professionals.

Authors:  Thomas W McNally; Gilles de Wildt; Graciela Meza; Connie M D Wiskin
Journal:  BMC Health Serv Res       Date:  2019-08-22       Impact factor: 2.655

4.  Outcomes and follow-up of patients treated for multidrug-resistant tuberculosis in Orel, Russia, 2002-2005.

Authors:  J S Cavanaugh; B Y Kazennyy; M L Nguyen; E V Kiryanova; E Vitek; T M Khorosheva; E Nemtsova; J P Cegielski
Journal:  Int J Tuberc Lung Dis       Date:  2012-06-11       Impact factor: 2.373

5.  Aggressive regimens for multidrug-resistant tuberculosis reduce recurrence.

Authors:  Molly F Franke; Sasha C Appleton; Carole D Mitnick; Jennifer J Furin; Jaime Bayona; Katiuska Chalco; Sonya Shin; Megan Murray; Mercedes C Becerra
Journal:  Clin Infect Dis       Date:  2012-12-07       Impact factor: 9.079

6.  Mortality among MDR-TB cases: comparison with drug-susceptible tuberculosis and associated factors.

Authors:  Kocfa Chung-Delgado; Sonia Guillen-Bravo; Alejandro Revilla-Montag; Antonio Bernabe-Ortiz
Journal:  PLoS One       Date:  2015-03-19       Impact factor: 3.240

7.  Recurrence after Successful Treatment of Multidrug-Resistant Tuberculosis in Taiwan.

Authors:  Meng-Yu Chen; Yi-Chun Lo; Wan-Chin Chen; Kwei-Feng Wang; Pei-Chun Chan
Journal:  PLoS One       Date:  2017-01-26       Impact factor: 3.240

8.  Use of predicted vital status to improve survival analysis of multidrug-resistant tuberculosis cohorts.

Authors:  Meredith B Brooks; Salmaan Keshavjee; Irina Gelmanova; Nataliya A Zemlyanaya; Carole D Mitnick; Justin Manjourides
Journal:  BMC Med Res Methodol       Date:  2018-12-11       Impact factor: 4.615

9.  Fluoroquinolone Resistance Mutation Detection Is Equivalent to Culture-Based Drug Sensitivity Testing for Predicting Multidrug-Resistant Tuberculosis Treatment Outcome: A Retrospective Cohort Study.

Authors:  Maha R Farhat; Karen R Jacobson; Molly F Franke; Devinder Kaur; Megan Murray; Carole D Mitnick
Journal:  Clin Infect Dis       Date:  2017-10-15       Impact factor: 9.079

10.  Aggressive regimens for multidrug-resistant tuberculosis decrease all-cause mortality.

Authors:  Carole D Mitnick; Molly F Franke; Michael L Rich; Felix A Alcantara Viru; Sasha C Appleton; Sidney S Atwood; Jaime N Bayona; Cesar A Bonilla; Katiuska Chalco; Hamish S F Fraser; Jennifer J Furin; Dalia Guerra; Rocio M Hurtado; Keith Joseph; Karim Llaro; Lorena Mestanza; Joia S Mukherjee; Maribel Muñoz; Eda Palacios; Epifanio Sanchez; Kwonjune J Seung; Sonya S Shin; Alexander Sloutsky; Arielle W Tolman; Mercedes C Becerra
Journal:  PLoS One       Date:  2013-03-13       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.